CN111707831A - Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition - Google Patents

Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition Download PDF

Info

Publication number
CN111707831A
CN111707831A CN202010684698.9A CN202010684698A CN111707831A CN 111707831 A CN111707831 A CN 111707831A CN 202010684698 A CN202010684698 A CN 202010684698A CN 111707831 A CN111707831 A CN 111707831A
Authority
CN
China
Prior art keywords
sle
kinase activity
rock kinase
substance
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010684698.9A
Other languages
Chinese (zh)
Inventor
何焱玲
符颖
张利平
陈乐�
王新洁
谭亚琪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Chaoyang Hospital
Original Assignee
Beijing Chaoyang Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Chaoyang Hospital filed Critical Beijing Chaoyang Hospital
Priority to CN202010684698.9A priority Critical patent/CN111707831A/en
Publication of CN111707831A publication Critical patent/CN111707831A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Abstract

The invention discloses application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE conditions. The invention provides application of a substance for detecting ROCK kinase activity in preparation of products. The product has the function of diagnosing or assisting in diagnosing the systemic lupus erythematosus. The product has the function of screening or assisting in screening the systemic lupus erythematosus patient. The product has the function of evaluating or assisting in evaluating the severity of the disease of the systemic lupus erythematosus patient. The inventor of the invention finds that ROCK kinase can be used as a new evaluation index of SLE disease activity. The invention has great application value for the auxiliary diagnosis of the SLE patient, the auxiliary screening of the SLE patient and the evaluation of the severity of the disease condition of the SLE patient.

Description

Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition
Technical Field
The invention relates to the use of ROCK kinase activity for aiding in the diagnosis of SLE and in the assessment of SLE conditions.
Background
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with complex clinical manifestations involving multiple organs simultaneously. The pathogenesis of SLE is not well defined at present. Systemic lupus erythematosus is better in women of childbearing age, most frequently in age range of 10-40 years, and the ratio of the number of women to men is about 9: 1. The prevalence rate of systemic lupus erythematosus is different from gender and age, and is the highest among black people, the second of Chinese Han nationality, the global average prevalence rate is (12-39)/10 ten thousand, the prevalence rate of black people is 100/10 ten thousand, and the prevalence rate of China is (30.13-70.41)/10 ten thousand.
Rho GTPase belongs to a member of Ras protein superfamily, is a small molecule GTP binding protein universally existing in eukaryotes, and plays an important role in the construction of cytoplasm skeletons. Rho kinase (ROCKs) is an important effector molecule downstream of Rho gtpase, a serine/threonine protein kinase, and plays an important role in the regulation of cytoskeleton formation, cell motility, migration, and gene expression.
Disclosure of Invention
The invention aims to provide application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition.
The invention provides an application of a substance for detecting ROCK kinase activity in preparing products; the product has the function of diagnosing or assisting in diagnosing the systemic lupus erythematosus.
The invention also provides the application of the substance for detecting the ROCK kinase activity in preparing products; the product has the function of screening or assisting in screening the systemic lupus erythematosus patient.
The invention also provides the application of the substance for detecting the ROCK kinase activity in preparing products; the product has the function of evaluating or assisting in evaluating the disease condition of the systemic lupus erythematosus patient.
The invention also provides the application of the substance for detecting the ROCK kinase activity in preparing products; the product has the function of evaluating or assisting in evaluating the severity of the disease of the systemic lupus erythematosus patient.
In any of the above applications, the substance for detecting ROCK kinase activity is a substance for detecting P-MYPT1 and a substance for detecting MYPT 1.
In any of the above applications, the substance for detecting ROCK kinase activity is a substance for detecting human P-MYPT1 and a substance for detecting human MYPT 1.
In any of the above applications, the substance for detecting P-MYPT1 comprises Phospho-MYPT1 antibody.
In any of the above applications, the substance for detecting P-MYPT1 further comprises horseradish enzyme labeled goat anti-rabbit IgG antibody.
In any of the above applications, the substance for detecting P-MYPT1 further comprises a substance for extracting total cellular protein from peripheral blood mononuclear cells.
In any of the above applications, the substance for detecting P-MYPT1 further includes a substance for extracting peripheral blood mononuclear cells from peripheral blood.
In any of the above applications, the substance for detecting MYPT1 comprises a MYPT1 antibody.
In any of the above applications, the substance for detecting MYPT1 further comprises horseradish enzyme labeled goat anti-rabbit IgG antibody.
In any of the above applications, the substance for detecting MYPT1 further includes a substance for extracting total cellular protein from peripheral blood mononuclear cells.
In any of the above applications, the substance for detecting MYPT1 further includes a substance for extracting peripheral blood mononuclear cells from peripheral blood.
In any of the above applications, the product is a kit.
The invention also provides a product comprising a substance for detecting ROCK kinase activity; the function of the product is as follows (a), (b), (c) or (d):
(a) diagnosing or aiding in diagnosing systemic lupus erythematosus;
(b) screening or auxiliary screening of systemic lupus erythematosus patients;
(c) evaluating or assisting in evaluating the condition of the patient with systemic lupus erythematosus;
(d) evaluating or assisting to evaluate the severity of the disease of the systemic lupus erythematosus patient.
In the product, the substances for detecting the ROCK kinase activity are substances for detecting P-MYPT1 and substances for detecting MYPT 1.
In the product, the substances for detecting the ROCK kinase activity are substances for detecting human P-MYPT1 and substances for detecting human MYPT 1.
In the product, the substance for detecting P-MYPT1 comprises Phospho-MYPT1 antibody.
In the product, the substance for detecting P-MYPT1 also comprises horseradish enzyme labeled goat anti-rabbit IgG antibody.
In the product, the substance for detecting P-MYPT1 also comprises a substance for extracting total cellular protein from peripheral blood mononuclear cells.
In the product, the substance for detecting P-MYPT1 also comprises a substance for extracting peripheral blood mononuclear cells from peripheral blood.
In the product, the substance for detecting MYPT1 comprises MYPT1 antibody.
In the product, the substance for detecting MYPT1 also comprises horseradish enzyme labeled goat anti-rabbit IgG antibody.
In the product, the substances for detecting MYPT1 also include substances for extracting total cellular protein from peripheral blood mononuclear cells.
In the product, the substance for detecting MYPT1 further includes a substance for extracting peripheral blood mononuclear cells from peripheral blood.
The product may specifically be a kit.
When the product has the function of (a), the product further comprises a carrier which is recorded with the following method:
if ROCK kinase activity > 0.55, the subject is or is candidate for a SLE patient.
When the product has the function of (b), the product further comprises a carrier in which the following method is described:
if ROCK kinase activity > 0.55, the subject is or is candidate for a SLE patient.
When the product has the function of (c), the product further comprises a carrier in which the following method is described:
if ROCK kinase activity is less than or equal to 0.71, the subject SLE patient is or is a candidate for a mildly active patient;
if ROCK kinase activity > 0.71 and ≤ 0.79, the subject SLE patient is or is a candidate for moderately active patient;
if ROCK kinase activity > 0.79, the subject SLE patient is or is candidate for a severely active patient.
The product also comprises a carrier which is recorded with the following detection methods:
(1) peripheral venous blood of the subject was taken and peripheral blood mononuclear cells were isolated.
(2) Taking peripheral blood mononuclear cells, and extracting total cell protein.
(3) Carrying out Western-Blot on the total cell protein to develop P-MYPT1 and MYPT1 protein bands;
(4) the gray values of the protein bands in the Western-Blot development image are analyzed to obtain P-MYPT1/MYPT 1.
The invention also protects the application of the ROCK kinase activity as a marker, which is (I) or (II) as follows:
the application of the compound (I) as a marker of a systemic lupus erythematosus patient;
(II) use as a marker for the severity of the condition in patients with systemic lupus erythematosus.
Any one of the above ROCK kinase activities is P-MYPT1/MYPT 1.
Any one of the above ROCK kinase activities is P-MYPT1 abundance/MYPT 1 abundance.
Any one of the above ROCK kinase activities is abundance of human P-MYPT 1/abundance of human MYPT 1.
Any one of the above ROCK kinase activities is P-MYPT1/MYPT1 in the total cellular protein of peripheral blood mononuclear cells.
Any one of the above ROCK kinase activities is P-MYPT1 abundance/MYPT 1 abundance in the total cellular protein of peripheral blood mononuclear cells.
The inventor finds that the ROCK kinase activity of the SLE patient is obviously higher than that of a healthy person, and the result indicates that Rho GTPase/ROCK signal channel participates in the generation and development process of systemic lupus erythematosus. Meanwhile, the more serious the SLE is, the higher the ROCK kinase activity is, and the ROCK kinase activity of the SLE patient is positively correlated with the SLEDAI-2000 score. ROCK kinase can be used as a new evaluation index of SLE disease activity. The invention has great application value for the auxiliary diagnosis of the SLE patient, the auxiliary screening of the SLE patient and the evaluation of the severity of the disease condition of the SLE patient.
Drawings
FIG. 1 shows a Western-Blot image of a normal cohort and a SLE cohort.
FIG. 2 is a graph comparing the ROCK kinase activities of the normal group and the SLE group.
FIG. 3 is a graph comparing the ROCK kinase activity of three SLE subgroup and the normal group.
FIG. 4 is a graph of the correlation of ROCK kinase activity with SLEDAI-2000 scores.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures in the following examples are conventional unless otherwise specified. The test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified. The quantitative tests in the following examples, all set up three replicates and the results averaged.
The normal group consisted of 95 healthy people. Healthy people group entry standard: selecting 95 healthy volunteers belonging to the Beijing Chaoyang hospital physical examination center of the university of capital medical science for physical examination at the same time; the volunteers need to be excluded from the history of liver and kidney diseases, diabetes or other autoimmune diseases and tumor diseases before being grouped.
The SLE group consisted of 36 SLE patients. 36 patients with SLE evaluated disease activity according to the SLE Activity index 2000(SLEDAI-2000) score, divided into three subgroups: mild activity group (20), moderate activity group (12), severe activity group (4).
See table 1 for SLE diagnostic criteria. Of the 11 in table 1, those who meet 4 or more, can be diagnosed with SLE following, except infection, tumor and other connective tissue diseases.
TABLE 1 diagnosis of systemic lupus erythematosus (ACR 1997 diagnosis)
Figure BDA0002587115380000041
The SLE Activity index 2000(SLEDAI-2000) scoring criteria are shown in Table 2. The total content is 0-4: there is substantially no activity. The total content is 5-9: mild activity. The total score is 10-14 points: moderate activity. The total score is 15 points and more than 15 points: and (4) performing severe activity. The total subrange value includes two extremes.
TABLE 2 Activity score for systemic lupus erythematosus (SLEDAI-2000)
Figure BDA0002587115380000042
Figure BDA0002587115380000051
Example 1 application of ROCK kinase Activity in auxiliary diagnosis of SLE
Study subjects: normal and SLE groups.
1. Peripheral venous blood of each of the subjects was collected, and Peripheral Blood Mononuclear Cells (PBMCs) were isolated.
2. And (3) adding the lymphocyte lysate into the peripheral blood mononuclear cells obtained in the step (1), incubating for 20min on ice (blowing every 5 min), centrifuging for 5min at 4 ℃ at 12000r/min, and absorbing supernatant, namely the cell total protein solution. Lymphocyte lysate: 1ml of RIPA lysate, 20. mu.l of 50 XCocktail protease inhibitor, 10. mu.l of PMSF, 10. mu.l of phosphorylase inhibitor A solution, and 10. mu.l of phosphorylase inhibitor B solution.
3. And (3) taking the total cell protein solution obtained in the step (2), and detecting the protein concentration by using a BCA method to determine the loading amount.
4. Western blotting (Western-Blot) was performed to visualize the protein bands of P-MYPT1 and MYPT1 and β -Actin in PBMCs. beta-Actin is an internal reference.
SDS-PAGE parameters: 8% of separation gel and 5% of concentrated gel; the initial voltage is 80V, when the protein runs to the interface of the concentrated gel-separation gel, the voltage is adjusted to 120V, then the electrophoresis is continued for about 30min, the power supply is turned off until the protein marker and the blue protein strip are observed to run to the bottom of the gel, and the electrophoresis is stopped.
For detecting P-MYPT 1: the primary antibody was Phospho-MYPT1 antibody, the primary antibody was diluted 1:1000 fold, Cell Signaling organism, USA, cat # 4563; the secondary antibody is horseradish enzyme labeled goat anti-rabbit IgG antibody, the working concentration of the secondary antibody is 1:1000 times diluted, and the product number of the secondary antibody is ZB-2301 by Beijing Zhonghua Jinqiao biotechnology company.
For detecting MYPT 1: the primary antibody was MYPT1 antibody, the working concentration of the primary antibody was 1:1000 fold dilution, American CellSignaling organism, cat # 2634; the secondary antibody is horseradish enzyme labeled goat anti-rabbit IgG antibody, the working concentration of the secondary antibody is 1:1000 times diluted, and the product number of the secondary antibody is ZB-2301 by Beijing Zhonghua Jinqiao biotechnology company.
The development method is ECL chemiluminescence development.
For an example, see FIG. 1 for a Western-Blot image of one normal panellist and one SLE panellist.
5. The grey scale values of the protein bands in the Western-Blot development Image were analyzed using Image J software, and the ROCK kinase activity was represented by P-MYPT1/MYPT 1.
The ROCK kinase activity of each subject in the normal group is shown in Table 3.
The ROCK kinase activity of each subject of the SLE cohort is shown in table 4.
The ROCK kinase activity of the normal group was 0.38. + -. 0.01. The ROCK kinase activity of the SLE group was 0.71. + -. 0.08. Figure 2 (p <0.05) shows a comparison of ROCK kinase activity between the normal and SLE groups.
The results show that ROCK kinase activity was significantly increased in the SLE group compared to the normal group.
The threshold for diagnosing SLE was set at ROCK kinase activity > 0.55, with a false negative rate of 0% and a false positive rate of 0%.
Example 2 application of ROCK kinase Activity in aiding diagnosis of SLE conditions
Study subjects: normal and SLE groups.
The SLEDAI-2000 scores for each subject in the SLE cohort are shown in Table 4.
ROCK kinase activity data was obtained for each subject in example 1.
The SLE group mild activity group had ROCK kinase activity of 0.65. + -. 0.03. The ROCK kinase activity of the intermediate activity group of the SLE group was 0.76. + -. 0.02. The ROCK kinase activity of SLE group severe activity group was 0.86. + -. 0.05. Figure 3 (p <0.05) compares the ROCK kinase activity of three SLE subset and normal groups.
The association of ROCK kinase activity with SLEDAI-2000 scores was analyzed using SPSS statistical software. The results are shown in FIG. 4. Pearson coefficient 0.931 × p < 0.05.
The results show that: the ROCK kinase activity of the mild activity group, the moderate activity group and the severe activity group is higher than that of the normal group; the SLE patients have a positive correlation between ROCK kinase activity and SLEDAI-2K score, and the more SLE is affected (the higher the SLEDAI-2000 score is), the higher the ROCK kinase activity is.
The ROCK kinase activity is more than 0.71 and less than or equal to 0.79 and is used as a medium activity threshold value for diagnosing SLE patients, the false negative rate is 0 percent, and the false positive rate is 0 percent.
The threshold value of the severe activity of the SLE patient is set to be that the ROCK kinase activity is more than 0.79, the false negative rate is 0 percent, and the false positive rate is 0 percent.
TABLE 3
Figure BDA0002587115380000071
Figure BDA0002587115380000081
Figure BDA0002587115380000091
TABLE 4
Figure BDA0002587115380000092
Figure BDA0002587115380000101

Claims (10)

1. Use of a substance for detecting ROCK kinase activity in the preparation of a product; the product has the function of diagnosing or assisting in diagnosing the systemic lupus erythematosus.
2. Use of a substance for detecting ROCK kinase activity in the preparation of a product; the product has the function of screening or assisting in screening the systemic lupus erythematosus patient.
3. Use of a substance for detecting ROCK kinase activity in the preparation of a product; the product has the function of evaluating or assisting in evaluating the disease condition of the systemic lupus erythematosus patient.
4. Use of a substance for detecting ROCK kinase activity in the preparation of a product; the product has the function of evaluating or assisting in evaluating the severity of the disease of the systemic lupus erythematosus patient.
5. Use according to any one of claims 1 to 4, wherein: the ROCK kinase activity is P-MYPT1 abundance/MYPT 1 abundance.
6. Use according to any one of claims 1 to 5, wherein: the substance for detecting the ROCK kinase activity is a substance for detecting P-MYPT1 and a substance for detecting MYPT 1.
7. The use of claim 6, wherein: the substance for detecting P-MYPT1 comprises Phospho-MYPT1 antibody, and the substance for detecting MYPT1 comprises MYPT1 antibody.
8. A product comprising a substance for detecting ROCK kinase activity; the function of the product is as follows (a), (b), (c) or (d):
(a) diagnosing or aiding in diagnosing systemic lupus erythematosus;
(b) screening or auxiliary screening of systemic lupus erythematosus patients;
(c) evaluating or assisting in evaluating the condition of the patient with systemic lupus erythematosus;
(d) evaluating or assisting to evaluate the severity of the disease of the systemic lupus erythematosus patient.
Use of ROCK kinase activity as a marker, as shown in (i) or (ii):
the application of the compound (I) as a marker of a systemic lupus erythematosus patient;
(II) use as a marker for the severity of the condition in patients with systemic lupus erythematosus.
10. The use of claim 9, wherein: the ROCK kinase activity is P-MYPT1 abundance/MYPT 1 abundance.
CN202010684698.9A 2020-07-16 2020-07-16 Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition Pending CN111707831A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010684698.9A CN111707831A (en) 2020-07-16 2020-07-16 Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010684698.9A CN111707831A (en) 2020-07-16 2020-07-16 Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition

Publications (1)

Publication Number Publication Date
CN111707831A true CN111707831A (en) 2020-09-25

Family

ID=72546432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010684698.9A Pending CN111707831A (en) 2020-07-16 2020-07-16 Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition

Country Status (1)

Country Link
CN (1) CN111707831A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233188A (en) * 1996-08-12 1999-10-27 吉富制药株式会社 Medicines comprising Rho kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233188A (en) * 1996-08-12 1999-10-27 吉富制药株式会社 Medicines comprising Rho kinase inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
YUANYUAN WANG 等: "Y-27632, a Rho-associated protein kinase inhibitor, inhibits systemic lupus erythematosus", vol. 88, pages 359 - 366 *
刘娜: "糖尿病合并肺结核患者外周血T淋巴细胞Rho激酶活性变化及其意义", vol. 23, no. 09, pages 1569 - 1577 *
彭世光 等: "Rho激酶活性与系统性红斑狼疮疾病活动的相关性研究", vol. 8, no. 8, pages 243 *
李文华 等: "Rho激酶对急性冠状动脉综合征患者复合心血管不良事件的影响", vol. 32, no. 32, pages 242 *
符颖: "ROCK激酶活性与SLE病情活动度的相关性研究", 万方医学网, pages 1 - 39 *

Similar Documents

Publication Publication Date Title
Bauer et al. Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk)
WO2021184412A1 (en) Enteric microorganism-based bipolar affective disorder biomarkers, and application thereof in screening
Gattas et al. Procalcitonin as a diagnostic test for sepsis: health technology assessment in the ICU
US10422004B2 (en) Diagnostic method for distinguishing forms of esophageal eosinophilia
CN110964778B (en) Use of enterobacteriaceae as ischemic cerebral apoplexy biomarker
Zorzi et al. Evolving interpretation of the athlete's electrocardiogram: from European Society of Cardiology and Stanford criteria, to Seattle criteria and beyond
CN107345970B (en) A kind of peripheral blood biomarker can be used for Schizophrenia diagnosis
CN105525029A (en) Seminal plasma piRNA markers reflecting male sperm activity or combination and application thereof
EP3786305A1 (en) Biomarker for depression and use thereof
Waaddegaard et al. Validation of a screening instrument for identifying risk behaviour related to eating disorders
Shosha et al. Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry
CN117288963A (en) Application of HFREP1 protein in preparation of kit for diagnosing acute myocardial infarction and cerebral infarction
CN111707831A (en) Application of ROCK kinase activity in auxiliary diagnosis of SLE and evaluation of SLE condition
Introcaso et al. Association of change in clinical status and change in the percentage of the CD4+ CD26− lymphocyte population in patients with Sezary syndrome
Tam et al. Skin tape stripping identifies gene transcript signature associated with allergic contact dermatitis
CN112481380B (en) Marker for evaluating anti-tumor immunotherapy reactivity and prognosis survival of late bladder cancer and application thereof
TWI758670B (en) Health risk assessment method
WO2017148951A1 (en) Gene signature for the prognosis of dry eye disease
CN111707832B (en) Use of ROCK kinase activity in aiding in the diagnosis of kidney damage
CN111721940A (en) Application of MICB protein expression quantity detection reagent in preparation of kit for identifying depressive disorder and bipolar disorder
Oyarzun et al. Myocarditis in the forensic setting
CN107058474B (en) Diagnostic kit for diagnosing acute mountain sickness through plasma microRNA-3591-3p
Gol et al. SVEAT score: Acute chest pain risk stratification
CN111707830A (en) Application of ROCK kinase activity in auxiliary diagnosis of lung injury
Lefevre et al. Gene profiling in active dermatitis lesions strengthens the diagnosis of allergic contact dermatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination